Teva Pharmaceuticals Stock Surges on Wall Street, CFO Optimistic About Further Gains
Translated & summarized from TheMarker by baba
Teva Pharmaceuticals is shifting its strategy to prioritize innovative drugs over generics, aiming for 20%-25% of sales from innovative drugs by the end of 2026. CFO Eli Kalif announced the accelerated change after the company's third-quarter 2026 financial reports. Teva's stock surged on Wall Street, with a target price between $48 and $52, and potential for further gains.
The story in 5 lines · by baba
- Teva Pharmaceuticals is accelerating its strategic shift to focus on innovative drugs over generics.
- The company aims for innovative drugs to constitute 20%-25% of sales by the end of 2026.
- CFO Eli Kalif announced the strategic shift following the release of Q3 2026 financial reports.
- Teva's stock surged on Wall Street, with a target price between $48 and $52.
- The CFO expressed optimism that the stock could climb an additional 10%.
Teva Pharmaceuticals is accelerating its strategic shift towards focusing on innovative drugs over generics, according to CFO Eli Kalif. Speaking on Tuesday after the company released its third-quarter 2026 financial reports, Kalif stated that the sales mix is changing significantly. In 2022, innovative drugs accounted for 10% of Teva's sales, with generics making up 90%. The company aims to increase the proportion of innovative drugs to 20%-25% by the end of 2026, with the remaining sales from generics. Kalif indicated that this transition might become more pronounced in the coming years.
Following these statements, Teva's stock experienced a surge on Wall Street. The target price set for the company's shares ranges between $48 and $52, with the potential for an additional 10% increase.
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.
